News and reporting on ovarian cancer.
The FDA approved FoundationOne CDx as a companion diagnostic for olaparib for first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.
The drug is for first-line maintenance therapy after BRCA-mutated advanced ovarian cancer patients respond to platinum chemo and the test will identify those with BRCA mutations.
The PARP inhibitor is approved as a maintenance treatment for advanced ovarian cancer patients who responded to first-line platinum chemotherapy and have BRCA mutations.
The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.
Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.
The firm will use the proceeds to further a validation study tracking the ability of its cell culture assay to predict patient response to cancer therapies.
The group published results showing its method can faithfully recapitulate genome-wide measures of DNA repair deficiency using much smaller sequencing panels.
The firm is seeking approval of myChoice HRD as a test that can identify ovarian, fallopian, or peritoneal cancer patients deficient in homologous recombination DNA repair.
Research presented at ACMG by Invitae suggests that clinically actionable variants in cancer patients are missed by germline testing that is not done with expanded panels.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.